{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:59:43Z","timestamp":1753891183115,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Extensive-stage small-cell lung cancer (ES-SCLC) has a dismal prognosis owing to its high aggressiveness, rapid drug resistance, and early metastasis. ES-SCLC responds well to first-line chemotherapy, and chemotherapy coupled with immunotherapy can further improve overall survival. However, the long-term survival of patients remains unsatisfactory because of its high recurrence rate and the poor efficacy of second-line treatment. Although local radiotherapy is an important component of the overall treatment for ES-SCLC, its value in the age of immunotherapy remains controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>A 54-year-old male with ES-SCLC achieved a complete response (CR), as determined using enhanced computed tomography (CT) after four cycles of immunochemotherapy (serplulimab, carboplatin, and etoposide). Whole-body positron emission tomography-CT was performed during maintenance treatment with serplulimab, which showed primary lung, liver, and bone metastatic lesions with CR. However, several mediastinal lymph nodes exhibited glucose metabolism uptake, and new lesions appeared on the head. The patient underwent palliative radiotherapy of the head and consolidative thoracic radiotherapy of the chest and continued maintenance treatment with serplulimab. Subsequent magnetic resonance imaging of the head suggested good control of metastatic lesions (CR). The patient received first-line immunotherapy for approximately 20 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This report presents a patient with ES-SCLC who underwent local radiotherapy in addition to serplulimab as maintenance therapy. Although the programmed death-ligand 1 (PD-L1) expression level was negative and a PD-1 inhibitor instead of a PD-L1 inhibitor was used, the patient did not experience significant pneumonia during treatment, and the efficacy of the current treatment was evident. This treatment model warrants further clinical investigation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1493740","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:32:33Z","timestamp":1730435553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Local radiotherapy in extensive-stage small-cell lung cancer sustainably boosts the clinical benefit of first-line immunotherapy: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Hongming","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuoni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zemin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3978\/j.issn.2218-6751.2016.01.03","article-title":"Small cell lung cancer (SCLC): No treatment advances in recent years","volume":"5","author":"Koinis","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: First-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2020.101.33","article-title":"Immune characteristics of small cell lung cancer","volume":"23","author":"Zhu","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.05.004","article-title":"Small cell lung cancer: Novel treatments beyond immunotherapy","volume":"86","author":"Meijer","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: A novel application for an established modality","volume":"95","author":"Ko","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): A randomized, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1334","DOI":"10.1016\/j.annonc.2023.10.096","article-title":"LBA93 extentorch: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)","volume":"34","author":"Cheng","year":"2023","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomized controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03017-z","article-title":"Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer","volume":"71","author":"Yu","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.001","article-title":"Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer","volume":"15","author":"Welsh","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.031","article-title":"Prospective single-arm phase 1 and 2 study: Ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer","volume":"109","author":"Perez","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8014","article-title":"Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175960","article-title":"Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102767","article-title":"194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide\/platinum (EP) as first-line treatment in ES-SCLC (lead): Efficacy and safety results","volume":"9","author":"Zhang","year":"2024","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-023-10784-8","article-title":"First-line atezolizumab\/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12672-023-00666-7","article-title":"Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: A retrospective study from a single cancer center","volume":"14","author":"Li","year":"2023","journal-title":"Discovery Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8001","article-title":"BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)","volume":"42","author":"Ohe","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100596","article-title":"124P Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC): Updated results of a phase Ib\/II trial","volume":"20","author":"Fang","year":"2023","journal-title":"Immuno-Oncol Technol"},{"key":"B28","article-title":"A phase Ib study of AK112, a PD-1\/VEGF bispecific antibody, in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer Asia Conference on Lung Cancer, Oral Sessions; 2022, Nara, Japan, Abstract Book","author":"Lu","year":"2022","journal-title":"Int Assoc Study Lung Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1255","DOI":"10.1016\/j.annonc.2022.07.1643","article-title":"1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE\u00ae), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)","volume":"33","author":"Gadgeel","year":"2022","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8089","article-title":"Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib\/II, open-label study","volume":"42","author":"Yu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/j.jtho.2023.09.658","article-title":"P2.14-06 A phase II trial assessing the safety and efficacy of tislelizumab combined with chemotherapy and autologous NK cells in patients with ES-SCLC","volume":"18","author":"Xu","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.951","article-title":"EP14.01-015 IMforte: A phase III study of lurbinectedin and atezolizumab versus atezolizumab as maintenance therapy in ES-SCLC","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8518","article-title":"Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","unstructured":"University of Washington. Identifier NCT05191797. Bomedemstat and maintenance immunotherapy for treatment of newly diagnosed extensive stage small cell lung cancer2022"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1493740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:32:37Z","timestamp":1730435557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1493740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2024.1493740"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1493740","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"1493740"}}